Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$4.17 USD
-0.12 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Corvus Pharmaceuticals, Inc. has a market cap of $292.45M, which represents its share price of $4.29 multiplied by its outstanding shares number of 68.17M. As a small-cap company, CRVS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CRVS 4.17 -0.12(-2.80%)
Will CRVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVS
Corvus Pharmaceuticals Q2 2025 Earnings Preview
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News
Corvus announces IND application approved by CDE of China NMPA to start trial
Corvus announces IND application approved by CDE of China NMPA to start trial
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)